Publikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (49)

2023

  1. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response

    Frontiers in Immunology, Vol. 14

  2. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study

    Cancers, Vol. 15, Núm. 14

  3. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

2022

  1. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

    British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969

  2. Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?

    Cancers, Vol. 14, Núm. 7

  3. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

    Clinical Cancer Research, Vol. 28, Núm. 20, pp. 4536-4550

  4. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review

    Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257

  2. Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report

    Frontiers in Immunology, Vol. 12

  3. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

    European Journal of Cancer, Vol. 148, pp. 134-145

  4. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

    British Journal of Cancer, Vol. 124, Núm. 9, pp. 1581-1591

2020

  1. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  2. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

  3. Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

    Contemporary Clinical Trials Communications, Vol. 20

  4. The evolving microbiome from pregnancy to early infancy: A comprehensive review

    Nutrients, Vol. 12, Núm. 1

  5. The second generation antibody-drug conjugate syd985 overcomes resistances to T-DM1

    Cancers, Vol. 12, Núm. 3

2019

  1. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

    Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  3. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology